Symphogen turns year-long deficits into first profitable year following Servier acquisition

Symphogen, which was acquired by French Servier two years ago, has succeeded in ending the financial year 2020/2021 with a double-digit million-dollar net result, despite a string of deficits in recent years.
Photo: Symphogen
Photo: Symphogen
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

Biotech firm Symphogen, which French pharmaceutical company Servier bought back in 2020, can now finally present financial results in the black, following years of deficits.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading